Prof Mike Rogers, BSc, PhD
Senior Principal Research Fellow and Head Bone Therapeutics Laboratory,
Garvan Institute of Medical Research
Conjoint Professor, UNSW Australia
Prof Rogers graduated from the University of Sheffield (UK) in 1989 with a first class honours in Biochemistry and in 1994 with a PhD in bone pharmacology. Prof Rogers moved to the University of Aberdeen in 1997 as a Lecturer, becoming Senior Lecturer in 1999 and Professor of Musculoskeletal Pharmacology in 2003. From 2005-2010, Prof Rogers led the Musculoskeletal Research Programme, a large, multi-disciplinary team that was recognised as a Centre of Excellence by the European League Against Rheumatism.
Prof Rogers served on several European Grant and Fellowship Committees, was a member of the Board of Directors of the International Bone & Mineral Society (IBMS), and a member of four Editorial Boards. He was awarded more than $10.7M in funding (a 5-year program grant, 37 project and equipment grants, 17 grants from 9 different pharmaceutical companies). Prof Rogers was twice the first recipient of international young investigator awards – the Iain T Boyle Award from the European Calcified Tissue Society and the Herbert Fleisch Award from the IBMS. Prof Rogers relocated to the Garvan Institute in 2012 to establish a Bone Therapeutics Laboratory within the expanding Bone Biology Division.
Prof Rogers is internationally recognized as an authority on bone cell biology and world leader in the molecular pharmacology of bisphosphonates, a blockbuster class of drugs used worldwide for common bone disorders including post-menopausal osteoporosis and cancer-associated bone disease. Prof Rogers’s team discovered two distinct molecular mechanisms of action of bisphosphonates that involve either the formation of toxic metabolites or inhibition of the cholesterol biosynthetic pathway in osteoclasts. These discoveries had a major impact in the field of bone biology, providing insights into the mode of action of these blockbuster drugs and their side-effects, and guiding efforts of the pharmaceutical industry in the design of potential new therapeutic agents and treatment strategies. Additionally, his research has also provided important insights into mechanisms regulating bone cell function and the causes of human bone diseases such as osteopetrosis.
Prof Rogers’s research currently seeks to identify the mechanisms underlying the additional beneficial effects of bisphosphonate drugs, particularly their anti-tumour actions and ability to increase survival of patients with multiple myeloma and breast cancer.